Bebbington C R, Renner G, Thomson S, King D, Abrams D, Yarranton G T
Celltech Ltd., Slough, U.K.
Biotechnology (N Y). 1992 Feb;10(2):169-75. doi: 10.1038/nbt0292-169.
We report a method for introducing a glutamine synthetase (GS) selectable marker into myeloma cells in which transfectants are selected by growth in a glutamine-free medium. Vector amplification can subsequently be selected using the specific inhibitor of GS, methionine sulphoximine (MSX). Using this system, DNA sequences encoding a chimeric B72.3 IgG4 antibody were expressed from hCMV-MIE promoters in NSO myeloma cells. A cell line was isolated after a single round of selection for vector amplification which contains approximately 4 copies of the vector, secretes 10-15 pg/cell/day cB72.3 antibody during exponential growth and can accumulate 560 mg/l antibody in a fed-batch air-lift fermentation system. Productivity is stable in the absence of MSX selection.
我们报道了一种将谷氨酰胺合成酶(GS)选择标记引入骨髓瘤细胞的方法,其中通过在无谷氨酰胺培养基中生长来选择转染子。随后可以使用GS的特异性抑制剂甲硫氨酸亚砜亚胺(MSX)来选择载体扩增。使用该系统,编码嵌合B72.3 IgG4抗体的DNA序列在NSO骨髓瘤细胞中由hCMV-MIE启动子表达。在一轮载体扩增选择后分离出一个细胞系,该细胞系含有约4个载体拷贝,在指数生长期间分泌10-15 pg/细胞/天的cB72.3抗体,并且在分批补料气升式发酵系统中可积累560 mg/l抗体。在没有MSX选择的情况下,生产力是稳定的。